$97M gene therapy consortium aims to give companies and rare disease families a ‘north star’
There was a time when Jocelyn Duff didn’t know how to answer her neighbors’ oft-asked question: “How is your daughter, Talia?”
Their small seaside community of Ipswich, MA, was pivotal in raising $1 million for an experimental gene therapy targeting Talia’s ultra-rare disease. Then came manufacturing setbacks and Covid-19 closed labs. She said a pharmaceutical company — for which Duff declined to name — deprioritized the therapy.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.